NFJ Investment Group LLC Makes New $18.39 Million Investment in Exelixis, Inc. $EXEL
NFJ Investment Group LLC has acquired a new stake of 338,045 shares in Exelixis, Inc. (NASDAQ:EXEL) worth approximately $18.39 million during the second quarter, bringing institutional ownership in the biotechnology company to 85.27%. This investment comes as Exelixis reported strong quarterly earnings, beating analyst estimates with $0.91 EPS and 10.6% year-over-year revenue growth. Despite a "Hold" consensus rating, analysts have recently raised price targets, reflecting a mixed but generally optimistic outlook for the company whose stock opened near its 52-week high.
51,642 Shares in Exelixis, Inc. $EXEL Purchased by NewEdge Wealth LLC
NewEdge Wealth LLC acquired a new stake of 51,642 shares in Exelixis, Inc. (NASDAQ:EXEL) during the second quarter, valued at approximately $2.81 million. Several other institutional investors also made new investments in the biotechnology company. Exelixis recently reported strong quarterly earnings, beating analyst estimates, and has an average "Hold" rating from analysts with an average price target of $50.07.
Abacus FCF Advisors LLC Invests $7.29 Million in Exelixis, Inc. $EXEL
Abacus FCF Advisors LLC has acquired a new stake worth approximately $7.29 million in Exelixis, Inc. (NASDAQ:EXEL) during the second quarter, bringing their total ownership to 0.05% of the biotechnology company. Other institutional investors like BlackRock Inc., AQR Capital Management LLC, Norges Bank, and Bank of New York Mellon Corp also made significant investments, while some insiders sold shares. Analyst ratings for Exelixis currently lean towards a "Hold" with a consensus price target of $50.07.
Out of sight, out of work? What’s driving remote job cuts
Some biopharma companies are reducing their remote workforce, forcing employees to choose between returning to the office, relocating, or resigning, as seen with EMD Serono and Exelixis. While many employers cite collaboration benefits for requiring on-site presence, other factors like program cuts or cost reductions also drive layoffs, affecting both remote and on-site staff. Experts suggest that job security remains a general industry risk, regardless of work location, though some candidates are wary of changing remote work policies.
Investigation launched into EXELIXIS officers for possible self-dealing harming shareholders
Kuehn Law, PLLC has initiated an investigation into whether certain officers and directors of EXELIXIS, Inc. breached their fiduciary duties through potential self-dealing. This probe could result in shareholder damages and calls for corporate governance reforms. Long-term EXEL shareholders are advised to contact the law firm for a free consultation to protect their rights.
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their fiduciary duties to shareholders, focusing on potential self-dealing. Long-term EXEL stockholders are encouraged to contact the firm for a free consultation to explore potential damages and corporate governance reforms, as participation helps maintain the integrity of financial markets.
EXELIXIS INC : BMO INITIATES COVERAGE WITH MARKET PERFORM RATING; PRICE TARGET $54
BMO has initiated coverage on Exelixis Inc. (EXEL.O) with a "Market Perform" rating. The firm has set a price target of $54 for the biotechnology company. This information was reported by Reuters.
JLB & Associates Inc. Acquires Shares of 48,849 Exelixis, Inc. $EXEL
JLB & Associates Inc. has purchased 48,849 shares of Exelixis, Inc. (NASDAQ:EXEL) for approximately $2.66 million, marking a new position in the biotechnology company. Institutional investors and hedge funds collectively own a significant 85.27% of Exelixis, which recently reported strong quarterly earnings exceeding estimates, though revenue was slightly below expectations. Despite mixed analyst sentiment resulting in an average "Hold" rating, the company's stock has seen positive movement, while insiders have sold a portion of their holdings.
BMO initiates Exelixis stock at Market Perform, cites patent cliff
BMO Capital initiated coverage on Exelixis (NASDAQ:EXEL) with a Market Perform rating and a $54.00 price target, citing concerns about a patent cliff in early 2030 for its main drug, cabozantinib. While the company's financial health is strong, BMO remains cautious as the follow-up drug, zanzalintinib, is not fully de-risked and its potential revenue may not offset the decline from cabozantinib. This comes despite Exelixis recently beating earnings estimates but lowering its full-year revenue guidance.
Pallas Capital Advisors LLC Invests $1.67 Million in Exelixis, Inc. $EXEL
Pallas Capital Advisors LLC has invested $1.67 million in Exelixis, Inc. by purchasing 30,721 shares in the second quarter. Institutional investors and hedge funds collectively own a significant 85.27% of the biotechnology company's stock. Exelixis recently reported strong quarterly earnings, beating EPS estimates, and has an average "Hold" rating from analysts with a consensus price target of $49.79.
27,109 Shares in Exelixis, Inc. $EXEL Purchased by Grandfield & Dodd LLC
Grandfield & Dodd LLC has acquired 27,109 shares of Exelixis, Inc. (NASDAQ:EXEL) during the second quarter, valued at approximately $1.48 million. This purchase contributes to the 85.27% of the stock already owned by institutional investors. Despite the company beating earnings estimates with $0.91 per share, revenue fell slightly short of expectations at $628.69 million, though it marked a 10.6% year-over-year increase.
Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky is investigating Exelixis (NASDAQ: EXEL) following a revenue miss in its second-quarter report, which caused shares to decline by approximately 7.9%. The company reported $628.7 million in revenue, below analyst consensus, and also lowered its full-year 2026 revenue outlook due to a slower-than-expected ramp in its neuroendocrine-tumor business. Shareholders who suffered losses are encouraged to contact the firm for a review of their claim.
Focus Partners Advisor Solutions LLC Buys Shares of 26,603 Exelixis, Inc. $EXEL
Focus Partners Advisor Solutions LLC initiated a new position in Exelixis, Inc. by purchasing 26,603 shares valued at approximately $1,447,000 during the second quarter. Other institutional investors like MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., Goldman Sachs Group Inc., and Sivia Capital Partners LLC also adjusted their holdings in the biotechnology company. Exelixis reported strong Q2 earnings, beating analyst estimates, and has a current market capitalization of $12.70 billion.
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) is investigating potential securities law violations by Exelixis, Inc. (NASDAQ: EXEL) after the company missed Q2 revenue estimates and lowered its full-year 2026 revenue guidance. The investigation focuses on whether Exelixis made false or misleading statements to investors, particularly concerning its neuroendocrine-tumor business for CABOMETYX. SBS encourages shareholders who suffered losses to participate in the investigation.
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Exelixis, Inc. (NASDAQ: EXEL) following the company missing Q2 revenue estimates and lowering its full-year 2026 revenue guidance. The investigation focuses on whether Exelixis made false or misleading statements to investors, particularly regarding its neuroendocrine-tumor business and the market position of CABOMETYX. SBS is inviting shareholders who have incurred losses to join the fraud investigation.
Exelixis (EXEL) Is Down 5.2% After Raising Q2 Profitability And Trimming 2026 Revenue Outlook – Has The Bull Case Changed?
Exelixis recently reported its Q2 2026 results, showing increased profitability but a slight reduction in its full-year 2026 revenue outlook to US$2.50 billion–US$2.55 billion. Despite the revenue trim, the core investment narrative remains focused on diversifying beyond cabozantinib through its oncology pipeline, with the December 2026 PDUFA decision for zanzalintinib being a key near-term catalyst. The revised guidance slightly tightens the gap between consensus expectations and more bullish scenarios, prompting investors to assess the company's transition strategy.
Farallon Capital (EXEL) discloses 13.99M-share Exelixis stake at $308M cost
Farallon Capital Management, L.L.C., and its affiliated investment partnerships, the Farallon Funds, have disclosed a beneficial ownership of 13,989,010 shares of Exelixis, Inc. (EXEL). This stake represents 5.6% of Exelixis' outstanding common stock and has an approximate net investment cost of $308,124,978. The information was reported in an amended Schedule 13D filing, which details the various entities and individuals exercising shared voting and dispositive power over these shares, all acquired through open-market transactions.
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL)
Levi & Korsinsky, LLP is investigating potential securities law violations concerning Exelixis (EXEL) after the company's Q2 revenue of $628.7 million missed Wall Street expectations, despite an adjusted EPS beat of $0.91. Investors who purchased EXEL and suffered losses are encouraged to contact the firm for a free case evaluation regarding potentially false or misleading statements about the company's commercial performance.
Exelixis Inc (EXEL) Director Mary Beckerle Sells 9,812 Shares
Exelixis Inc (EXEL) Director Mary Beckerle recently sold 9,812 shares for approximately $526,500, continuing a trend of insider selling with 22 insider sells against only 1 insider buy over the past year. The stock is considered modestly overvalued by GuruFocus's GF Value at $53.66, against a fair value of $45.58, despite its P/E ratio being lower than the industry median. This insider activity and valuation, along with more gurus trimming positions, suggest caution for investors.
Exelixis (EXEL) Q2 2026 Earnings Call Transcript
Exelixis (EXEL) reported its Q2 2026 earnings, with total revenues reaching $628.7 million, a 10.6% increase year-over-year, driven by cabozantinib sales. The company updated its full-year 2026 revenue guidance downwards due to a more gradual sales ramp in the neuroendocrine tumor indication but reduced R&D expense guidance to maintain capital discipline. Exelixis is focusing on developing zanzalintinib as its next franchise molecule, with several pivotal trials underway and a PDUFA date for zanza plus atezolizumab in metastatic colorectal cancer set for December 3, 2026.
Annex Advisory Services LLC Makes New Investment in Exelixis, Inc. $EXEL
Annex Advisory Services LLC has acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL), purchasing 25,918 shares valued at approximately $1.41 million during the second quarter. This investment comes as Exelixis reported strong quarterly earnings, surpassing EPS expectations, though revenue slightly missed analyst estimates. Despite significant insider selling over the past 90 days, institutional investors collectively hold a substantial 85.27% of the company, and analysts maintain a consensus "Hold" rating with an average price target just below the stock's opening price.
Exelixis, Inc. (EXEL) Stock Forecasts
Argus has lowered its target price for Exelixis Inc. (EXEL) to $56.00, while the current price stands at $50.44. Exelixis is a biopharmaceutical company focused on discovering, developing, and commercializing cancer treatments.
Exelixis director Mary Beckerle sells $526k in shares
Exelixis director Mary C. Beckerle sold 9,812 shares of the company's common stock for $526,511 on August 10, 2026, under a Rule 10b5-1 trading plan. Following the sale, she beneficially owns 16,079 shares, including RSUs. This transaction occurred amidst a recent 3.5% stock drop, though shares have returned 31% over the past year, while the company reported mixed Q2 2026 financial results with an earnings beat but a downward revision of full-year revenue guidance.
Exelixis director Mary Beckerle sells $526k in shares
Exelixis director Mary Beckerle sold 9,812 shares of the company's common stock for over $526,000, executed under a Rule 10b5-1 trading plan. This transaction leaves her with 16,079 beneficially owned shares, including RSUs. The sale occurred as Exelixis's stock saw a recent decline but maintained a strong annual return, with InvestingPro suggesting the stock is currently undervalued.
Insider Selling: Exelixis (NASDAQ:EXEL) Director Sells $526,511.92 in Stock
Exelixis (NASDAQ:EXEL) Director Mary Beckerle sold 9,812 shares of company stock, valued at $526,511.92, under a pre-arranged Rule 10b5-1 trading plan. This transaction reduced her ownership by 37.9% to 16,079 shares. The biotechnology company recently reported strong quarterly earnings, beating analyst estimates with $0.91 EPS and revenue up 10.6% year over year, though revenue slightly missed expectations.
Exelixis (EXEL) director Beckerle sells 9,812 shares via Rule 10b5-1 plan
Exelixis director Mary C. Beckerle sold 9,812 shares of common stock on August 10, 2026, at a weighted average price of $53.66 per share, under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Beckerle's holdings consist of 16,079 shares, which are to be issued upon the vesting of restricted stock units. This sale was publicly disclosed via a Form 4 SEC filing.
AQR Capital discloses 11.0M-share Exelixis (EXEL) position at 4.39% ownership
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have disclosed a beneficial ownership of 11,023,943 shares of Exelixis, Inc. common stock, representing 4.39% of the class. The filing indicates shared voting power over 10,935,221 shares and shared dispositive power over all 11,023,943 shares. This information was reported in an amended Schedule 13G/A filing, confirming AQR Capital Management, LLC as a wholly-owned subsidiary of AQR Capital Management Holdings, LLC.
EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis
SueWallSt is investigating potential securities claims against Exelixis (NASDAQ: EXEL) following a reduction and narrowing of its full-year 2026 revenue guidance. The company's shares declined after it cited a slower-than-expected ramp in its neuroendocrine-tumor business, contradicting earlier reiterations of its financial outlook. Shareholders who experienced losses are encouraged to submit their information for a free evaluation.
Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)
Levi & Korsinsky, LLP has announced an investigation into Exelixis (EXEL) after the company reiterated its full-year 2026 financial guidance on May 5, 2026, only to lower and narrow its revenue outlook weeks later, causing a stock decline. The investigation focuses on whether Exelixis made misleading statements regarding its revenue guidance and the commercial ramp of its neuroendocrine-tumor business, particularly concerning when management first identified the slower ramp. Investors who suffered losses after purchasing EXEL stock are encouraged to contact Levi & Korsinsky for a free evaluation of their claims.
EXELIXIS, INC. SEC Filing (Aug 10, 2026)
This article reports on an SEC Form 144 filing by Exelixis, Inc. (EXEL) on August 10, 2026. The filing indicates a proposed sale of 9,812 shares of common stock with an aggregate market value of $526,496.22, acquired on May 29, 2026, through a restricted stock acquisition from the issuer. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
Bank of America Corp DE Sells 578,181 Shares of Exelixis, Inc. $EXEL
Bank of America Corp DE reduced its stake in Exelixis, Inc. by 26% during the first quarter, selling 578,181 shares and retaining 1.64 million shares valued at approximately $70.5 million. This divestment comes as Exelixis reported solid Q2 earnings, beating EPS estimates, but faced mixed analyst sentiment and a lowered 2026 revenue outlook due to slower-than-expected product launches. Despite the institutional selling, Exelixis's stock performance remains near its 52-week high, although many analysts maintain a "Hold" rating.
(EXEL) as a Liquidity Pulse for Institutional Tactics
This article analyzes Exelixis Inc. (NASDAQ: EXEL) using AI models to provide institutional trading strategies. It highlights a weak near-term sentiment but strong long-term outlook, with a significant 26.9:1 risk-reward setup. Three distinct strategies—Position Trading, Momentum Breakout, and Risk Hedging—are detailed, alongside multi-timeframe signal analysis.
Amundi Sells 121,348 Shares of Exelixis, Inc. $EXEL
Amundi reduced its stake in Exelixis, Inc. by 77.9% in the first quarter, selling 121,348 shares but still retaining 34,398 shares valued at $1.48 million. Despite Amundi's sell-off, other major institutions like AQR Capital and Goldman Sachs increased their holdings, with institutional investors collectively owning 85.27% of EXEL. Exelixis reported strong Q2 earnings with EPS of $0.91, surpassing estimates, and revenue growth of 10.6%, though analysts maintain a "Hold" rating with an average price target below the current trading price.
Exelixis, Inc. Stock 12‑Month Price Target Raised to $52.62, Implies 7% Downside
Exelixis, Inc.'s average stock price target has been raised from $52.25 to $52.62 by 16 analysts, suggesting a potential 7% downside based on the August 5 closing price. Despite the raised target implying a decrease, the consensus rating for EXEL remains a "Buy" from 21 covering analysts.
EXELIXIS INC EXELIXIS ORD SHS (0IJO.L) Q4 FY2025 earnings call transcript
Exelixis reported Q4 2025 revenues of $599M, primarily driven by a 6% year-over-year increase in U.S. CABOMETYX sales to $547M, with full-year 2025 U.S. CABOMETYX revenue reaching $2.12B, up 17% year-over-year. The company is preparing for a potential late 2026 launch of zanzalintinib for CRC, with a PDUFA date of December 3, and anticipates continued growth in its RCC and NET indications. The earnings call transcript covers the financial results and future outlook.
Quantinno Capital Management LP Boosts Holdings in Exelixis, Inc. $EXEL
Quantinno Capital Management LP significantly increased its stake in Exelixis, Inc. by 44.3% in the first quarter, now holding 115,592 shares valued at approximately $4.96 million. This increase occurred despite mixed analyst ratings and recent insider selling. Exelixis reported strong second-quarter adjusted earnings but lowered its 2026 revenue outlook due to slower product uptake, leading to varied sentiment among investors and analysts.
EXELIXIS INC : LEERINK PARTNERS CUTS TO MARKET PERFORM FROM OUTPERFORM
Leerink Partners has downgraded its rating for Exelixis Inc (EXEL.O) from "Outperform" to "Market Perform." This change indicates a revised outlook on the pharmaceutical company's stock performance. The update was reported by Reuters.
Exelixis (EXEL) Is Down 6.7% After Cutting 2026 Revenue Outlook Amid Oncology Investment Pivot
Exelixis (EXEL) saw its stock drop 6.7% after cutting its 2026 revenue outlook to $2.50 billion–$2.55 billion. This revision came despite solid Q2 earnings and is attributed to slower growth in the neuroendocrine tumor indication and continued heavy investment in its zanzalintinib pipeline and share repurchases. The company's investment narrative now hinges on cabozantinib's ability to generate strong cash flow while zanzalintinib develops, with a key FDA decision for metastatic colorectal cancer expected by December 2026.
EXELIXIS, INC. Q2 2026: Revenue $628.69M, EPS $0.82— 10-Q Summary
EXELIXIS, INC. reported strong second-quarter 2026 results with revenue of $628.69M and diluted EPS of $0.82, showing significant year-over-year growth due to increased product demand and price gains. Key drivers included CABOMETYX sales, progress in pipeline development with zanzalintinib, and expanded clinical trials. The company also highlighted increased R&D focus and the completion of a substantial stock repurchase program.
Exelixis Inc (EXEL) Beats EPS Estimate with $0.82 and Reports Revenue of $628.7 Million -- Is the Stock Overvalued?
Exelixis Inc (EXEL) reported strong financial results for Q2 2026, surpassing analyst expectations with total revenues of $628.7 million and a GAAP diluted EPS of $0.82. The biopharmaceutical company, known for its cancer treatments like cabozantinib, updated its fiscal year 2026 guidance, projecting total revenues between $2.500 billion to $2.550 billion. Despite solid financial performance and growth potential, GuruFocus indicates the stock is currently overvalued by 31.8%, raising caution for potential investors.
Exelixis, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:EXEL) 2026-08-06
Exelixis, Inc. published its Q2 2026 earnings call presentation. The company reported EPS of $0.91, beating estimates by $0.02, but revenue of $628.69M missed expectations by $7.46M, despite a 10.63% year-over-year increase. The slide deck provides detailed information discussed during the earnings call.
EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View
Exelixis, Inc. (EXEL) reported mixed results for Q2 2026, beating earnings estimates with 82 cents EPS but missing revenue forecasts at $628.7 million. The company lowered its full-year 2026 revenue guidance due to a slower-than-expected ramp-up of its neuroendocrine tumor indication for Cabometyx. Despite the revenue miss, Exelixis continues to advance its pipeline, including zanzalintinib, and has expanded its share repurchase program.
Exelixis Q2 2026 Earnings Call Transcript
Exelixis reported strong Q2 2026 financial results, with cabozantinib franchise revenue growing 10% year-over-year in the U.S. and 13% globally. The company updated its full-year revenue guidance to reflect a more gradual ramp-up in the neuroendocrine tumor (NET) indication, citing the indolent nature of NET patients. Exelixis highlighted the anticipated FDA decision for zanzalintinib in third-line-plus colorectal cancer as a key priority for expanding its oncology franchise and discussed its robust development pipeline for zanzalintinib in various other tumor types.
EXELIXIS ($EXEL) Releases Q2 2026 Earnings
EXELIXIS ($EXEL) announced its Q2 2026 earnings, reporting $0.91 per share, which surpassed estimates. However, the company's revenue of $628.69 million fell short of expectations. Following the announcement, the stock experienced a 5.23% decline.
Exelixis Q2 2026 earnings: Cabozantinib growth lifts revenue and EPS
Exelixis reported strong Q2 2026 earnings, with revenue reaching $628.7 million, a 10.6% increase year-over-year, and diluted EPS rising to $0.82. This growth was primarily driven by higher sales volume of cabozantinib, though the company lowered its full-year revenue outlook. Exelixis continues to invest in clinical trials and zanzalintinib's regulatory process, while also repurchasing shares to boost per-share earnings.
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Exelixis reported strong second-quarter 2026 financial results, with total revenues reaching $628.7 million and GAAP diluted EPS of $0.82. The company highlighted the continued growth of its cabozantinib franchise and significant progress in its zanzalintinib development program, including ongoing regulatory review for metastatic colorectal cancer and the initiation of new pivotal trials. Exelixis also updated its full-year 2026 financial guidance and continued its stock repurchase program.
Transcript : Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026
This article is a transcript of Exelixis, Inc.'s Q2 2026 Earnings Call held on August 5, 2026. During the call, Exelixis updated its fiscal 2026 revenue guidance to $2.50B-$2.55B, lower than FactSet's estimate of $2.60B. The company also reported Q2 revenue of $628.7M and adjusted EPS of $0.91, both compared against analyst estimates.
Earnings Flash (EXEL) Exelixis, Inc. Reports Q2 Revenue $628.7M, vs. FactSet Est of $636.4M
Exelixis, Inc. (EXEL) reported its Q2 revenue at $628.7 million, falling short of the FactSet estimate of $636.4 million. The company also updated its fiscal year 2026 revenue guidance to a range of $2.50 billion to $2.55 billion, which is below the FactSet estimate of $2.60 billion. Despite missing revenue estimates, Exelixis posted Q2 adjusted EPS of $0.91 per share, exceeding the FactSet estimate of $0.85.
Exelixis earnings on deck as generic threat looms
Exelixis Inc. is set to report second-quarter earnings, facing scrutiny over its flagship cancer drug, Cabometyx, due to an escalating patent dispute and the emergence of a generic alternative. Investors are also keenly watching the commercialization prospects for its next-generation pipeline drug, zanzalintinib, and the company's ability to maintain double-digit growth amidst competitive pressures. Analysts anticipate earnings of $0.84 per share on revenue of $633.8 million, with the stock currently trading near its 52-week high.
Royal Bank of Canada Grows Stock Holdings in Exelixis, Inc. $EXEL
Royal Bank of Canada increased its holdings in Exelixis, Inc. by 24.6% in the first quarter, now owning 694,131 shares valued at approximately $29.8 million. This increase comes as Exelixis reported strong quarterly earnings, beating analyst estimates, with revenue up 10% year-over-year. Despite recent insider stock sales totaling $10.6 million and a "Hold" consensus rating from analysts, the company's shares are trading near their 52-week high.
